Progestogen-releasing intrauterine systems versus other forms of reversible contraceptives for contraception

Abstract

Progestogen-releasing intrauterine systems versus other forms of reversible contraceptives for contraception.

An evaluation of the simultaneous use of the levonorgestrel-releasing intrauterine device (LNG-IUS, Mirena®) combined with endometrial ablation in the management of menorrhagia

“……”

An evaluation of the simultaneous use of the levonorgestrel-releasing intrauterine device (LNG-IUS, Mirena®) combined with endometrial ablation in the management of menorrhagia

“……”

Association of Hormonal Contraceptive Use With Adverse Health Outcomes

“…Fourteen of the 60 associations (23.3%) were nominally statistically significant ( P ≤ .05) based on random-effects models. A total of 21 associations (35.0%) had high heterogeneity ( I 2 > 50%).…”

“…Of those, 102 articles (32.8%) were eligible for preliminary data extraction (eFigure 1 in the Supplement ). After the selection criteria for the overlapping meta-analyses were applied ( Table 2 ), 58 articles 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , …”

“…Thirteen eligible meta-analyses 24 , 25 , 26 , 27 , 35 , 36 , 42 , 72 , 73 , 74 , 79 , 80 , 81 described 60 potential associations, including 60 individual study estimates of adverse health outcomes associated with hormonal contraceptive exposure. The median number of RCTs per meta-analysis was 2 (IQR, 2-3), with a median sample of 91 participants (IQR, 75-154 participants) and a follow-up duration ranging from 3 months to 10 years.…”

“…Evaluation of the methodological quality of 13 meta-analyses 24 , 25 , 26 , 27 , 35 , 36 , 42 , 72 , 73 , 74 , 79 , 80 , 81 using the AMSTAR-2 tool revealed that 8 meta-analyses 24 , 27 , 35 , 36 , 42 , 73 , 74 (61.5%) were of high quality, 3 meta-analyses 25 , 26 , 72 (23.1%) were of low quality, and 2 meta-analyses 80 , 81 (15.4%) were of critically low quality ( Table 2 ; eTable 5 in the Supplement ).…”

An evaluation of the simultaneous use of the levonorgestrel-releasing intrauterine device (LNG-IUS, Mirena®) combined with endometrial ablation in the management of menorrhagia

“……”

Association of Hormonal Contraceptive Use With Adverse Health Outcomes

“…Fourteen of the 60 associations (23.3%) were nominally statistically significant ( P ≤ .05) based on random-effects models. A total of 21 associations (35.0%) had high heterogeneity ( I 2 > 50%).…”

“…Of those, 102 articles (32.8%) were eligible for preliminary data extraction (eFigure 1 in the Supplement ). After the selection criteria for the overlapping meta-analyses were applied ( Table 2 ), 58 articles 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , …”

“…Thirteen eligible meta-analyses 24 , 25 , 26 , 27 , 35 , 36 , 42 , 72 , 73 , 74 , 79 , 80 , 81 described 60 potential associations, including 60 individual study estimates of adverse health outcomes associated with hormonal contraceptive exposure. The median number of RCTs per meta-analysis was 2 (IQR, 2-3), with a median sample of 91 participants (IQR, 75-154 participants) and a follow-up duration ranging from 3 months to 10 years.…”

“…Evaluation of the methodological quality of 13 meta-analyses 24 , 25 , 26 , 27 , 35 , 36 , 42 , 72 , 73 , 74 , 79 , 80 , 81 using the AMSTAR-2 tool revealed that 8 meta-analyses 24 , 27 , 35 , 36 , 42 , 73 , 74 (61.5%) were of high quality, 3 meta-analyses 25 , 26 , 72 (23.1%) were of low quality, and 2 meta-analyses 80 , 81 (15.4%) were of critically low quality ( Table 2 ; eTable 5 in the Supplement ).…”

An evaluation of the simultaneous use of the levonorgestrel-releasing intrauterine device (LNG-IUS, Mirena®) combined with endometrial ablation in the management of menorrhagia

“……”

Association of Hormonal Contraceptive Use With Adverse Health Outcomes

“…Fourteen of the 60 associations (23.3%) were nominally statistically significant ( P ≤ .05) based on random-effects models. A total of 21 associations (35.0%) had high heterogeneity ( I 2 > 50%).…”

“…Of those, 102 articles (32.8%) were eligible for preliminary data extraction (eFigure 1 in the Supplement ). After the selection criteria for the overlapping meta-analyses were applied ( Table 2 ), 58 articles 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , …”

“…Thirteen eligible meta-analyses 24 , 25 , 26 , 27 , 35 , 36 , 42 , 72 , 73 , 74 , 79 , 80 , 81 described 60 potential associations, including 60 individual study estimates of adverse health outcomes associated with hormonal contraceptive exposure. The median number of RCTs per meta-analysis was 2 (IQR, 2-3), with a median sample of 91 participants (IQR, 75-154 participants) and a follow-up duration ranging from 3 months to 10 years.…”

“…Evaluation of the methodological quality of 13 meta-analyses 24 , 25 , 26 , 27 , 35 , 36 , 42 , 72 , 73 , 74 , 79 , 80 , 81 using the AMSTAR-2 tool revealed that 8 meta-analyses 24 , 27 , 35 , 36 , 42 , 73 , 74 (61.5%) were of high quality, 3 meta-analyses 25 , 26 , 72 (23.1%) were of low quality, and 2 meta-analyses 80 , 81 (15.4%) were of critically low quality ( Table 2 ; eTable 5 in the Supplement ).…”